{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:48:47Z","timestamp":1757310527605,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19H03615"],"award-info":[{"award-number":["JP19H03615"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ck0106253"],"award-info":[{"award-number":["JP19ck0106253"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s12185-022-03369-x","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T19:31:57Z","timestamp":1651865517000},"page":"534-543","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Introduction of the T315I gatekeeper mutation of BCR\/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR\/Cas9 system"],"prefix":"10.1007","volume":"116","author":[{"given":"Thao T. T.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minori","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Harama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koshi","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Goi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Inukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"issue":"11","key":"3369_CR1","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1182\/blood.V91.11.3995","volume":"91","author":"S Faderl","year":"1998","unstructured":"Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998;91(11):3995\u20134019.","journal-title":"Blood"},{"issue":"6","key":"3369_CR2","first-page":"957","volume":"10","author":"S Schlieben","year":"1996","unstructured":"Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R, et al. Incidence and clinical outcome of children with BCR\/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia. 1996;10(6):957\u201363.","journal-title":"Leukemia"},{"issue":"5","key":"3369_CR3","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","volume":"108","author":"B Wassmann","year":"2006","unstructured":"Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood. 2006;108(5):1469\u201377. https:\/\/doi.org\/10.1182\/blood-2005-11-4386.","journal-title":"Blood"},{"issue":"1","key":"3369_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11864-019-0603-z","volume":"20","author":"I Abou Dalle","year":"2019","unstructured":"Abou Dalle I, Jabbour E, Short NJ, Ravandi F. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Treat Options Oncol. 2019;20(1):4. https:\/\/doi.org\/10.1007\/s11864-019-0603-z.","journal-title":"Curr Treat Options Oncol"},{"issue":"9","key":"3369_CR5","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra013339","volume":"346","author":"DG Savage","year":"2002","unstructured":"Savage DG, Antman KH. Imatinib mesylate\u2014a new oral targeted therapy. N Engl J Med. 2002;346(9):683\u201393. https:\/\/doi.org\/10.1056\/NEJMra013339.","journal-title":"N Engl J Med"},{"issue":"7","key":"3369_CR6","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/cncr.28522","volume":"120","author":"S Soverini","year":"2014","unstructured":"Soverini S, De Benedittis C, Papayannidis C, Paolini S, Venturi C, Iacobucci I, et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome\u2013positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014;120(7):1002\u20139. https:\/\/doi.org\/10.1002\/cncr.28522.","journal-title":"Cancer"},{"issue":"12","key":"3369_CR7","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","volume":"94","author":"E Weisberg","year":"2006","unstructured":"Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94(12):1765\u20139. https:\/\/doi.org\/10.1038\/sj.bjc.6603170.","journal-title":"Br J Cancer"},{"issue":"6","key":"3369_CR8","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2015-03-636548","volume":"126","author":"DY Kim","year":"2015","unstructured":"Kim DY, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015;126(6):746\u201356. https:\/\/doi.org\/10.1182\/blood-2015-03-636548.","journal-title":"Blood"},{"issue":"7","key":"3369_CR9","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","volume":"110","author":"O Ottmann","year":"2007","unstructured":"Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007;110(7):2309\u201315. https:\/\/doi.org\/10.1182\/blood-2007-02-073528.","journal-title":"Blood"},{"issue":"5682","key":"3369_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (New York, NY). 2004;305(5682):399\u2013401. https:\/\/doi.org\/10.1126\/science.1099480.","journal-title":"Science (New York, NY)"},{"issue":"6","key":"3369_CR11","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","volume":"128","author":"P Rousselot","year":"2016","unstructured":"Rousselot P, Coud\u00e9 MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela J-M, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128(6):774\u201382. https:\/\/doi.org\/10.1182\/blood-2016-02-700153.","journal-title":"Blood"},{"issue":"1","key":"3369_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/CCO.0b013e328011a25f","volume":"19","author":"M Warmuth","year":"2007","unstructured":"Warmuth M, Kim S, Gu XJ, Xia G, Adrian F. Ba\/F3 cells and their use in kinase drug discovery. Curr Opin Oncol. 2007;19(1):55\u201360. https:\/\/doi.org\/10.1097\/CCO.0b013e328011a25f.","journal-title":"Curr Opin Oncol"},{"issue":"5883","key":"3369_CR13","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1126\/science.1155390","volume":"320","author":"R Sandberg","year":"2008","unstructured":"Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB. Proliferating cells express mRNAs with shortened 3\u2019 untranslated regions and fewer microRNA target sites. Science (New York, NY). 2008;320(5883):1643\u20137. https:\/\/doi.org\/10.1126\/science.1155390.","journal-title":"Science (New York, NY)"},{"issue":"4","key":"3369_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.cell.2009.06.016","volume":"138","author":"C Mayr","year":"2009","unstructured":"Mayr C, Bartel DP. Widespread shortening of 3\u2019UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell. 2009;138(4):673\u201384. https:\/\/doi.org\/10.1016\/j.cell.2009.06.016.","journal-title":"Cell"},{"issue":"6","key":"3369_CR15","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccr.2008.04.018","volume":"13","author":"MJ Bueno","year":"2008","unstructured":"Bueno MJ, de Castro IP, de Cedr\u00f3n MG, Santos J, Calin GA, Cigudosa JC, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008;13(6):496\u2013506. https:\/\/doi.org\/10.1016\/j.ccr.2008.04.018.","journal-title":"Cancer Cell"},{"issue":"12","key":"3369_CR16","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1158\/1535-7163.mct-08-0482","volume":"7","author":"TS Lee","year":"2008","unstructured":"Lee TS, Ma W, Zhang X, Giles F, Cortes J, Kantarjian H, et al. BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Mol Cancer Ther. 2008;7(12):3834\u201341. https:\/\/doi.org\/10.1158\/1535-7163.mct-08-0482.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"3369_CR17","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.leukres.2008.07.023","volume":"33","author":"C Hirase","year":"2009","unstructured":"Hirase C, Maeda Y, Takai S, Kanamaru A. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor. Leuk Res. 2009;33(3):450\u20139. https:\/\/doi.org\/10.1016\/j.leukres.2008.07.023.","journal-title":"Leuk Res"},{"issue":"6","key":"3369_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.14715\/cmb\/2018.64.6.5","volume":"64","author":"Y Hekmatshoar","year":"2018","unstructured":"Hekmatshoar Y, Ozkan T, Altinok Gunes B, Bozkurt S, Karadag A, Karabay AZ, et al. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms. Cell Mol Biol (Noisy-le-grand). 2018;64(6):23\u201330.","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"6","key":"3369_CR19","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","volume":"101","author":"FX Mahon","year":"2003","unstructured":"Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003;101(6):2368\u201373. https:\/\/doi.org\/10.1182\/blood.V101.6.2368.","journal-title":"Blood"},{"issue":"3","key":"3369_CR20","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"FX Mahon","year":"2000","unstructured":"Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96(3):1070\u20139.","journal-title":"Blood"},{"issue":"7","key":"3369_CR21","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/cncr.20131","volume":"100","author":"B Scappini","year":"2004","unstructured":"Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, et al. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr\/Abl protein. Cancer. 2004;100(7):1459\u201371. https:\/\/doi.org\/10.1002\/cncr.20131.","journal-title":"Cancer"},{"issue":"7","key":"3369_CR22","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1074\/jbc.M109.039206","volume":"285","author":"H Yuan","year":"2010","unstructured":"Yuan H, Wang Z, Gao C, Chen W, Huang Q, Yee JK, et al. BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. J Biol Chem. 2010;285(7):5085\u201396. https:\/\/doi.org\/10.1074\/jbc.M109.039206.","journal-title":"J Biol Chem"},{"issue":"11","key":"3369_CR23","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.3109\/10428194.2011.591013","volume":"52","author":"C Tang","year":"2011","unstructured":"Tang C, Schafranek L, Watkins DB, Parker WT, Moore S, Prime JA, et al. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. Leuk Lymphoma. 2011;52(11):2139\u201347. https:\/\/doi.org\/10.3109\/10428194.2011.591013.","journal-title":"Leuk Lymphoma"},{"issue":"6121","key":"3369_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR\/Cas systems. Science (New York, NY). 2013;339(6121):819\u201323. https:\/\/doi.org\/10.1126\/science.1231143.","journal-title":"Science (New York, NY)"},{"key":"3369_CR25","doi-asserted-by":"publisher","unstructured":"Maruyama T, Dougan SK, Truttmann MC, Bilate AM, Ingram JR, Ploegh HL. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol. 2015;33:538. https:\/\/doi.org\/10.1038\/nbt.3190. https:\/\/www.nature.com\/articles\/nbt.3190#supplementary-information.","DOI":"10.1038\/nbt.3190"},{"issue":"6","key":"3369_CR26","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1172\/JCI90825","volume":"127","author":"M Nieborowska-Skorska","year":"2017","unstructured":"Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, et al. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Investig. 2017;127(6):2392\u2013406. https:\/\/doi.org\/10.1172\/JCI90825.","journal-title":"J Clin Investig"},{"issue":"4","key":"3369_CR27","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2010-09-307256","volume":"118","author":"A Slupianek","year":"2011","unstructured":"Slupianek A, Dasgupta Y, Ren S-Y, Gurdek E, Donlin M, Nieborowska-Skorska M, et al. Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. Blood. 2011;118(4):1062\u20138. https:\/\/doi.org\/10.1182\/blood-2010-09-307256.","journal-title":"Blood"},{"issue":"1","key":"3369_CR28","doi-asserted-by":"publisher","first-page":"9966","DOI":"10.1038\/s41598-018-27767-6","volume":"8","author":"M Tamai","year":"2018","unstructured":"Tamai M, Inukai T, Kojika S, Abe M, Kagami K, Harama D, et al. T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR\/Cas9 system. Sci Rep. 2018;8(1):9966. https:\/\/doi.org\/10.1038\/s41598-018-27767-6.","journal-title":"Sci Rep"},{"issue":"7035","key":"3369_CR29","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917\u201321. https:\/\/doi.org\/10.1038\/nature03445.","journal-title":"Nature"},{"issue":"11","key":"3369_CR30","doi-asserted-by":"publisher","first-page":"djx059","DOI":"10.1093\/jnci\/djx059","volume":"109","author":"JA Nickoloff","year":"2017","unstructured":"Nickoloff JA, Jones D, Lee S-H, Williamson EA, Hromas R. Drugging the cancers addicted to DNA repair. J Natl Cancer Inst. 2017;109(11):djx059. https:\/\/doi.org\/10.1093\/jnci\/djx059.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"3369_CR31","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1182\/blood-2002-06-1770","volume":"101","author":"K Uno","year":"2003","unstructured":"Uno K, Inukai T, Kayagaki N, Goi K, Sato H, Nemoto A, et al. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome\u2013positive leukemia cells. Blood. 2003;101(9):3658\u201367. https:\/\/doi.org\/10.1182\/blood-2002-06-1770.","journal-title":"Blood"},{"issue":"7","key":"3369_CR32","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","volume":"97","author":"Y Kano","year":"2001","unstructured":"Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 2001;97(7):1999\u20132007. https:\/\/doi.org\/10.1182\/blood.V97.7.1999.","journal-title":"Blood"},{"issue":"21","key":"3369_CR33","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1182\/blood.V116.21.3432.3432","volume":"116","author":"P Rousselot","year":"2010","unstructured":"Rousselot P, Boucher S, Etienne G, Nicolini FE, Chauzit E, Makhoul PC, et al. Pharmacokinetics of dasatinib as a first line therapy in newly diagnosed CML patients (OPTIM dasatinib trial): correlation with safety and response. Blood. 2010;116(21):3432. https:\/\/doi.org\/10.1182\/blood.V116.21.3432.3432.","journal-title":"Blood"},{"key":"3369_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1756-8722-5-23","volume":"5","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Miura M, Scott SA, Niioka T, Sawada K. Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation. J Hematol Oncol. 2012;5:23. https:\/\/doi.org\/10.1186\/1756-8722-5-23.","journal-title":"J Hematol Oncol."},{"issue":"2","key":"3369_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11899-015-0254-5","volume":"10","author":"M Yilmaz","year":"2015","unstructured":"Yilmaz M, Abaza Y, Jabbour E. Selecting the best frontline treatment in chronic myeloid leukemia. Curr Hematol Malig Rep. 2015;10(2):145\u201357. https:\/\/doi.org\/10.1007\/s11899-015-0254-5.","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"3369_CR36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O'Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401\u201312. https:\/\/doi.org\/10.1016\/j.ccr.2009.09.028.","journal-title":"Cancer Cell"},{"issue":"19","key":"3369_CR37","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1306494.","journal-title":"N Engl J Med"},{"issue":"9","key":"3369_CR38","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.exphem.2010.04.017","volume":"38","author":"S Okabe","year":"2010","unstructured":"Okabe S, Tauchi T, Ohyashiki K. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation. Exp Hematol. 2010;38(9):765\u201372. https:\/\/doi.org\/10.1016\/j.exphem.2010.04.017.","journal-title":"Exp Hematol"},{"issue":"4","key":"3369_CR39","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/10428190801896103","volume":"49","author":"O Hantschel","year":"2008","unstructured":"Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma. 2008;49(4):615\u20139. https:\/\/doi.org\/10.1080\/10428190801896103.","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"3369_CR40","doi-asserted-by":"publisher","first-page":"9809","DOI":"10.1158\/0008-5472.can-08-1008","volume":"68","author":"FX Mahon","year":"2008","unstructured":"Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Can Res. 2008;68(23):9809\u201316. https:\/\/doi.org\/10.1158\/0008-5472.can-08-1008.","journal-title":"Can Res"},{"issue":"8","key":"3369_CR41","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/ccr3.1032","volume":"5","author":"J Noetzli","year":"2017","unstructured":"Noetzli J, Gavillet M, Masouridi-Levrat S, Duchosal M, Spertini O. T315I clone selection in a Ph+ all patient under low-dose ponatinib maintenance. Clin Case Rep. 2017;5(8):1320\u20132. https:\/\/doi.org\/10.1002\/ccr3.1032.","journal-title":"Clin Case Rep"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03369-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03369-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03369-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T18:45:53Z","timestamp":1664304353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03369-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["3369"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03369-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2022,5,6]]},"assertion":[{"value":"22 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}